BioNexus Gene Lab Corp. (BGLC) Spending and interest coverage
- R&D / revenue · 12 months: Value 1.73%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.73% | Research and development expense / revenue. Period ending 2026-06-30. $54.13K ÷ $3.13M × 100 ≈ 1.73% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 54.13K USD | Research and Development Expense |
| Revenue | 3.13M USD | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -2.56M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $54.13K | $3.13M | (m) | $-2.56M | (m) | 1.73% | (m) | (m) | (m) |
| 2026-03-31 | $53.02K | $5.31M | (m) | $-2.89M | (m) | 1.00% | (m) | (m) | (m) |
| 2025-12-31 | $50.67K | $7.42M | $794.77K | $-2.97M | (m) | 0.68% | 10.70% | (m) | (m) |
| 2025-09-30 | $56.97K | $9.47M | (m) | $-2.35M | (m) | 0.60% | (m) | (m) | (m) |
| 2025-06-30 | $52.53K | $9.55M | (m) | $-2.98M | (m) | 0.55% | (m) | (m) | (m) |
| 2025-03-31 | $48.17K | $9.27M | (m) | $-2.11M | (m) | 0.52% | (m) | (m) | (m) |
| 2024-12-31 | $47.51K | $9.51M | (m) | $-1.57M | (m) | 0.50% | (m) | (m) | (m) |
| 2024-09-30 | (m) | $9.26M | (m) | $-899.73K | $19.52K | (m) | (m) | -46.10× | Reported |
| 2024-06-30 | (m) | $9.18M | (m) | $-2.09M | $17.58K | (m) | (m) | -118.90× | Reported |
| 2024-03-31 | (m) | $9.78M | (m) | $-2.62M | $16.14K | (m) | (m) | -162.40× | Reported |
| 2023-12-31 | (m) | $9.77M | (m) | $-2.59M | $13.93K | (m) | (m) | -186.20× | Reported |
| 2023-09-30 | (m) | $10.34M | (m) | $-2.97M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $10.36M | (m) | $-510.73K | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $10.28M | (m) | $-376.50K | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $10.93M | (m) | $-291.18K | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $11.33M | (m) | $32.58K | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $12.34M | (m) | $470.43K | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $12.94M | (m) | $748.42K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $13.36M | (m) | $1.06M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $14.24M | (m) | $851.72K | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $13.76M | (m) | $716.39K | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $11.77M | (m) | $542.39K | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $11.39M | (m) | $1.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $83.06K | (m) | $-268.83K | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $83.76K | (m) | $-259.43K | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | $-262.60K | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $126.95K | (m) | $-275.70K | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $212.33K | (m) | $59.90K | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |